Literature DB >> 1763067

Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.

S E Ealick1, Y S Babu, C E Bugg, M D Erion, W C Guida, J A Montgomery, J A Secrist.   

Abstract

Competitive inhibitors of the salvage pathway enzyme purine-nucleoside phosphorylase (purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1) have been designed by using the three-dimensional structure of the enzyme as determined by x-ray crystallography. The process was an iterative one that utilized interactive computer graphics, Monte Carlo-based conformational searching, energy minimization, and x-ray crystallography. The proposed compounds were synthesized and tested by an in vitro assay. Among the compounds designed and synthesized are the most potent competitive inhibitors of purine nucleoside phosphorylase thus far reported.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763067      PMCID: PMC53171          DOI: 10.1073/pnas.88.24.11540

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  BIOCHEMICAL AND CARCINOSTATIC EFFECTS OF 2'-DEOXYTHIOGUANOSINE.

Authors:  G A LEPAGE; I G JUNGA; B BOWMAN
Journal:  Cancer Res       Date:  1964-06       Impact factor: 12.701

2.  Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution.

Authors:  S E Ealick; S A Rule; D C Carter; T J Greenhough; Y S Babu; W J Cook; J Habash; J R Helliwell; J D Stoeckler; R E Parks
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

Review 3.  Design of enzyme inhibitors using iterative protein crystallographic analysis.

Authors:  K Appelt; R J Bacquet; C A Bartlett; C L Booth; S T Freer; M A Fuhry; M R Gehring; S M Herrmann; E F Howland; C A Janson
Journal:  J Med Chem       Date:  1991-07       Impact factor: 7.446

4.  Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin.

Authors:  A Bzowska; E Kulikowska; D Shugar
Journal:  Z Naturforsch C J Biosci       Date:  1990 Jan-Feb

Review 5.  Design of purine nucleoside phosphorylase inhibitors.

Authors:  J D Stoeckler; S E Ealick; C E Bugg; R E Parks
Journal:  Fed Proc       Date:  1986-11

6.  Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.

Authors:  D S Shewach; J W Chern; K E Pillote; L B Townsend; P E Daddona
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

7.  Inhibitors of purine nucleoside phosphorylase: effects of 9-deazapurine ribonucleosides and synthesis of 5'-deoxy-5'-iodo-9-deazainosine.

Authors:  J D Stoeckler; J B Ryden; R E Parks; M Y Chu; M I Lim; W Y Ren; R S Klein
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

Review 8.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization.

Authors:  S K Burley; G A Petsko
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

9.  Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.

Authors:  R B Gilbertsen; M E Scott; M K Dong; L M Kossarek; M K Bennett; D J Schrier; J C Sircar
Journal:  Agents Actions       Date:  1987-08

10.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Authors:  J Erickson; D J Neidhart; J VanDrie; D J Kempf; X C Wang; D W Norbeck; J J Plattner; J W Rittenhouse; M Turon; N Wideburg
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

View more
  25 in total

1.  Decoys for docking.

Authors:  Alan P Graves; Ruth Brenk; Brian K Shoichet
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

2.  Benchmarking sets for molecular docking.

Authors:  Niu Huang; Brian K Shoichet; John J Irwin
Journal:  J Med Chem       Date:  2006-11-16       Impact factor: 7.446

3.  NMR structure-based drug design.

Authors:  S W Fesik
Journal:  J Biomol NMR       Date:  1993-05       Impact factor: 2.835

4.  Modulating Enzyme Catalysis through Mutations Designed to Alter Rapid Protein Dynamics.

Authors:  Ioanna Zoi; Javier Suarez; Dimitri Antoniou; Scott A Cameron; Vern L Schramm; Steven D Schwartz
Journal:  J Am Chem Soc       Date:  2016-03-08       Impact factor: 15.419

Review 5.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

6.  Analysis of cyclic and acyclic nicotinic cholinergic agonists using radioligand binding, single channel recording, and nuclear magnetic resonance spectroscopy.

Authors:  K A McGroddy; A A Carter; M M Tubbert; R E Oswald
Journal:  Biophys J       Date:  1993-02       Impact factor: 4.033

7.  PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR).

Authors:  D J Wilburn; M K Dong; R B Gilbertsen
Journal:  Agents Actions       Date:  1993

8.  Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock.

Authors:  Zsolt Bikadi; Eszter Hazai
Journal:  J Cheminform       Date:  2009-09-11       Impact factor: 5.514

9.  PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat blood in vitro.

Authors:  M K Dong; R B Gilbertsen
Journal:  Agents Actions       Date:  1993

10.  Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase.

Authors:  Suwipa Saen-Oon; Mahmoud Ghanem; Vern L Schramm; Steven D Schwartz
Journal:  Biophys J       Date:  2008-01-30       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.